Research programme: therapeutic antibodies - Miikana/Light Chain Bioscience
Latest Information Update: 08 Nov 2019
At a glance
- Originator Miikana Therapeutics; NovImmune SA
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Autoimmune disorders; Cancer
Most Recent Events
- 16 Jan 2006 Miikana Therapeutics has been acquired by EntreMed
- 10 Nov 2003 Preclinical trials in Autoimmune disorders in USA (unspecified route)
- 10 Nov 2003 Preclinical trials in Cancer in USA (unspecified route)